Project Grant R01HL176666
Award Date
1/15/25
Completion Date
12/30/28
Dollars Obligated
$767K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $324,440 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of North Carolina at Chapel Hill on September 17, 2024. This grant will fund a research project to assess the contribution of epigenetics to cardiovascular disease risk in African American women. The project aims to identify epigenetic biomarkers associated with cardiovascular disease and its environmental determinants, and evaluate whether...
The University of North Carolina at Chapel Hill received a $1,602,792 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837). The grant, effective January 15, 2025 through November 30, 2028, supports research to examine the phenotypic consequences of lipoprotein(a) [Lp(a)] in diverse global populations. The research aims to identify and characterize both anticipated and unanticipated effects of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $641,544 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to the University of North Carolina at Chapel Hill (UNC-CH). The grant will fund the development of novel machine learning methods to address critical challenges in analyzing complex biomedical data related to heart, lung, blood, and sleep (HLBS) disorders. Specifically, the project aims to: 1) propose advanced machine learning...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $751,747 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of North Carolina at Chapel Hill (UNC-CH). The grant, effective January 1, 2025 through November 30, 2028, will support research on the regulation of cardiomyocyte (heart muscle cell) maturation by the enzyme CARM1. The project aims to define the critical role of CARM1 in...
This federal Project Grant award, totaling $685,884 and granted by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research at the University of North Carolina at Chapel Hill focused on understanding how the protein C1 inhibitor regulates coagulation and thrombosis. The project aims to evaluate the molecular mechanisms by which C1 inhibitor prevents venous thrombosis, assess the impact of C1 inhibitor deficiency on coagulation and thrombosis...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $445,500 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to Cleveland State University (CSU) for the project "Chemoenzymatic Semisynthesis of Proteoglycan and Its Cofactor Activities". The project aims to synthesize recombinant thrombomodulin (TM) conjugates with chondroitin sulfate glycosaminoglycan (CSGAG) and liposomes to investigate the roles of CSGAG and lipids in the activation of...
This federal Project Grant award of $229,971 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop and test novel hydrogel patches to prevent air leaks after lung surgery. The award supports researchers at the University of North Carolina at Chapel Hill in achieving the following: Optimizing the degradation rate and elastic properties of the anisotropic and auxetic hydrogel patches through in vitro studies (Aim...
The University of North Carolina at Chapel Hill (UNC-CH) was awarded a $142,804 Project Grant under the National Heart, Lung, and Blood Institute's (NHLBI) Cardiovascular Diseases Research program (CFDA 93.837). The project aims to (1) investigate whether cough symptoms can predict responses to pharmacologic and nonpharmacologic treatments for cough hypersensitivity syndrome (CHS), and (2) determine the feasibility of a pilot randomized controlled trial of a nonpharmacologic treatment,...
This federal Project Grant award of $471,364 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the roles of synthetic glycosaminoglycan mimetics in regulating megakaryopoiesis and thrombopoiesis. The project, led by a K12 postdoctoral scholar at the University of North Texas, aims to determine the nature of interaction between a specific glycosaminoglycan mimetic compound (G4.1) and the...
This $488,026 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a flexible bioelectronic microarchitecture that integrates a capillary-like media delivery network and tissue-like sensing network to improve cardiac tissue engineering. The University of Massachusetts is the prime recipient, with a sub-award to Harvard University to collaborate on the project. The key products and services to...